Allergen-specific adaptive immune system

The allergen-specific adaptive immune system is the specialized network of B and T lymphocytes that orchestrates the body's response to specific environmental proteins, or allergens (Akdis & Akdis, 2014, JACI). In allergic individuals, this system is pathologically skewed toward a T-helper 2 (Th2) phenotype, which promotes the production of allergen-specific IgE (sIgE) antibodies by B cells (Larche et al., 2006, Nature Reviews Immunology). These IgE antibodies sensitize mast cells and basophils, leading to the rapid release of inflammatory mediators upon subsequent allergen exposure. Therapeutic strategies such as Allergen Immunotherapy (AIT) aim to reprogram this system by inducing regulatory T cells (Tregs) and B cells (Bregs), which secrete anti-inflammatory cytokines like IL-10 and TGF-beta to suppress the allergic cascade (Shamji & Durham, 2017, JACI). Additionally, modern biologics interact with this system by neutralizing IgE (Omalizumab) or blocking key Th2 cytokines like IL-4 and IL-13 (Dupilumab) to prevent the downstream effects of allergen recognition (FDA, Xolair/Dupixent Labels). While not a single molecular target, the allergen-specific adaptive immune system is the fundamental biological framework addressed by both desensitization therapies and targeted immunomodulators in the treatment of allergic diseases.

Other names

Allergen-specific immune responseAdaptive allergic immune responseType I hypersensitivity pathway

Induction of immune tolerance through the expansion of regulatory T (Treg) and B (Breg) cells, suppression of Th2-mediated inflammation, and the production of allergen-specific IgG4 blocking antibodies (Akdis & Akdis, 2014, JACI; Larche et al., 2006, Nature Reviews Immunology).